Study Of Matrix Metalloproteinases(MMP) And Tissue Inhibitors Of Metalloproteinases(TIMP) In Renal Transplant Recipients(RTR)- Rejectors Versus Stable Graft
1Department of Immunopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India, 2Vaccines and Immunity, Nationwide Children's Hospital, Columbus, OH, 3Department of Renal Transplant Surgery, Post Graduate Institute of Medical Education and Research, Chandigarh, India, 4Department of Histopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India, 5Department of Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarh, India, 6Department of Renal Transplant Surgery, Fortis Hospital, Mohali, Mohali, India
Meeting: 2022 American Transplant Congress
Abstract number: 9047
Keywords: Graft survival, Kidney transplantation, Metalloproteinases, Rejection
Topic: Basic Science » Basic Science » 07 - Vascular, Lymphatic, Stromal and Parenchymal Cell Biology
Session Information
Session Name: Vascular, Lymphatic, Stromal and Parenchymal Cell Biology
Session Type: Poster Abstract
Date: Sunday, June 5, 2022
Session Time: 7:00pm-8:00pm
Presentation Time: 7:00pm-8:00pm
Location: Hynes Halls C & D
*Purpose: Our study aimed to shed light on the role of serum levels of MMP and their inhibitors- TIMP in renal allograft rejection.
*Methods: This was a retrospective study done in patients who underwent renal transplant in a tertiary care center in the year 2012. The patients were divided into two groups – Rejecters and Non-Rejecters based upon histopathological diagnosis of acute transplant rejection (within one year after transplantation). Of the total 250 renal transplants, 38 were rejecters. 32 non-rejecters and a control group comprising of 20 healthy transplant kidney donors were also selected randomly. The values of MMP1, MMP2, MMP9, TIMP1 and TIMP2 were analysed using sandwich ELISA (enzyme linked immunosorbent assay) in serum samples stored at -80⁰C (collected within one month of rejection episode in rejecters and at 12th month after transplant in non-rejecters).
*Results: The study included 38 rejecters (32 men and 6 women, mean age-32.8±9.5 years), 32 non-rejecters (28 men and 4 women, mean age-36.1±11.8 years) and 20 controls (4 men and 16 women, mean age-42.5±12.7 years). Compared to the control population, renal transplant recipients showed significantly higher median serum values (p<0.001) of MMP1 (5.3 & 10.2 ng/ml), MMP2 (0.9 & 3.5 ng/ml), MMP9 (68.06 & 379.89 ng/ml), TIMP1 (0.0 & 11.2 ng/ml) and TIMP2 (0.0 & 13.2 ng/ml). Rejecters and non-rejecters when separately compared with the control group also showed significantly higher values of these proteins. However, there were no significant differences (p>0.05) in the median serum values between rejecters and non-rejecters – MMP1 (10.5 & 9.2 ng/ml), MMP2 (3.7 & 3.2 ng/ml), MMP9 (379.89 & 437.29 ng/ml), TIMP1 (20.3 & 3.0 ng/ml) and TIMP2 (13.2 & 9.7ng/ml).
*Conclusions: Both MMPs and TIMPs were significantly higher in renal transplant recipients compared to the healthy controls. We could identify dysregulation of the MMP/TIMP system in both transplant rejection and stable graft. However, the levels of these factors were not significantly different between acute rejecters and stable grafts in first year post transplantation. Hence long term studies are required to identify the imbalance of MMP/TIMP system in chronic graft rejection.
To cite this abstract in AMA style:
Tom JP, Dhital R, Sharma A, Aggarwal R, Nada R, Ramachandran R, Anand S, Minz M, Minz R. Study Of Matrix Metalloproteinases(MMP) And Tissue Inhibitors Of Metalloproteinases(TIMP) In Renal Transplant Recipients(RTR)- Rejectors Versus Stable Graft [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/study-of-matrix-metalloproteinasesmmp-and-tissue-inhibitors-of-metalloproteinasestimp-in-renal-transplant-recipientsrtr-rejectors-versus-stable-graft/. Accessed May 11, 2025.« Back to 2022 American Transplant Congress